Wednesday, January 10, 2018 8:40:22 AM
9 minutes ago - DJNF
Propanc Biopharma Engages Alan Morell of Creative Management Partners as Senior Strategic Advisor to CEO and Board of Directors
Mr. Morell to Focus on Branding, Growth Strategy and Market Positioning
PR Newswire
MELBOURNE, Australia, Jan. 10, 2018
MELBOURNE, Australia, Jan. 10, 2018 /PRNewswire/ -- Propanc Biopharma Inc. (OTCQB: PPCB) ("Propanc Biopharma" or "the Company"), a clinical stage biopharmaceutical company focusing on development of new and proprietary treatments for cancer patients suffering from solid tumors such as pancreatic, ovarian and colorectal cancers, today announced the engagement of Mr. Alan Morell as a Senior Strategic Advisor for the Company, focusing on branding, growth strategy and market positioning. Mr. Morell currently serves as Chief Executive Officer of Creative Management Partners LLC, an internationally recognized Media and Public Relations firm and will be advising the Company on a consulting basis.
"For a number of months I held numerous discussions with Alan and observed his important contacts at the highest level among Fortune 500 Companies, including within the Pharma and Biotech sectors," said James Nathanielsz, Propanc Biopharma's Chief Executive Officer. "Alan is highly respected on Wall Street within the Microcap sector and has excellent contacts across all Media. We look forward to maximizing the exciting growth potential of the Company with Alan's involvement, as we advance our lead product, PRP, towards a First-In-Human study in 2018."
"It is an incredibly enlightening journey to witness the advancement of this innovative technology and dedication of the management team at Propanc Biopharma under CEO James Nathanielsz," said Mr. Morell, Senior Strategic Advisor to the CEO at Propanc Biopharma. "I share James' belief that PRP have the ability to direct cancer stem cells (CSCs) to become benign, converting cancerous cells into normal cells by reprogramming gene expression in CSCs, but not healthy cells. Our job is to get this positive word out."
Currently progressing towards a First-In-Human study, PRP aims to prevent tumor recurrence and metastasis from solid tumors. Eighty percent of all cancers are solid tumors and metastasis is the main cause of patient death from cancer. According to the World Health Organization, 8.2 million people died from cancer in 2012. Consequently, a report by IMS Health states innovative therapies are driving the global oncology market to meet demand, which is expected to reach $150 billion by 2020. The Company's initial target patient populations are pancreatic, ovarian and colorectal cancers, representing an estimated combined market segment of $14 billion in 2020, according to GBI Research.
To view Propanc Biopharma's "Mechanism of Action" video on anti-cancer product candidate, PRP, please click on the following link: http://www.propanc.com/news-media/video
To be added to Propanc Biopharma's email distribution list, please click on the following link: http://ir.propanc.com/email-alerts and submit the online request form.
About Creative Management Partners LLC, Agent Alan Morell, Consulting and Advisory:
Creative Management Partners assists clients with Brand Growth Strategy, which includes identifying relevant cancer support associations for media campaigns, such as video news releases, social media, and print and online placement for business-focused publications. Through Creative Management Partners, Mr. Morell coordinates with news affiliates including Fox, MSNBC, and CNBC, Fortune, Time among others, for both live and taped appearances and interviews. At Creative Management Partners LLC, Mr. Morell's client list ranges from select individuals within Pharma, Medical, Literary; Broadcast; Sports, Entertainment and the Arts. Creative Management Partners is headquartered in Beverly Hills, California, with partner offices in New York, Toronto and London. With over 30 years in the industry, Mr. Morell has led more than 2,500 Brand Strategy campaigns in both the public and private sectors.
Recent PPCB News
- Biopharma on a Tear After Certificate of Grant from Japanese Patent Office • AllPennyStocks.com • 06/25/2024 04:26:00 PM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • ELMGF • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM